JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Melphalan; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
- Indications Myelofibrosis
- Focus Therapeutic Use
- 08 Apr 2019 Results (n=28) assessing pre-hematopoietic cell transplant Ruxolitinib in patients with mylelofibrosis published in the Bone Marrow Transplantation
- 27 Mar 2019 Planned primary completion date changed from 1 Mar 2019 to 11 Mar 2021.
- 15 Jan 2019 Planned number of patients changed from 33 to 48.